FIELD: biotechnology.
SUBSTANCE: modulating polynucleotide is described for reducing or inhibiting the gene expression in a cell, where the specified modulating polynucleotide contains: (a) a stem and a loop that form a “stem-loop” structure, (b) the first flanking region located in the direction 5' from the specified accompanying chain, where the specified first flanking region contains 5'-end flanking sequence and 5'-end spacer sequence, where the first flanking region contains a nucleotide sequence, which is at least 90% identical to SEQ ID NO:5, and (c) the second flanking region located in the direction 3' from the specified guide chain, where the specified second flanking region contains 3'-end spacer sequence and 3'-end flanking region, where the specified second flanking region contains a nucleotide sequence, which is at least 90% identical to SEQ ID NO:21.
EFFECT: invention expands the arsenal of means for the treatment of central nervous system (CNS) disease.
28 cl, 2 dwg, 4 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHODS AND COMPOSITIONS FOR TREATMENT OF HUNTINGTON'S CHOREA | 2017 |
|
RU2764587C2 |
RECOVERED NUCLEIC ACID WHICH CODES FVIII-BDD-BASED FUSION PROTEIN AND HETEROLOGOUS SIGNAL PEPTIDE, AND USE THEREOF | 2022 |
|
RU2818229C2 |
VACCINE BASED ON AAV5 FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-CoV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2020 |
|
RU2783313C1 |
VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY TO THE SARS-CoV-2 VIRUS AND/OR THE PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2761879C1 |
AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-COV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-COV-2 | 2020 |
|
RU2760301C1 |
GENE THERAPY OF HYPOPHOSPHATEMIC DISEASES ASSOCIATED WITH FIBROBLAST GROWTH FACTOR 23 | 2020 |
|
RU2815545C2 |
NEW LIVER TARGETING ADENO-ASSOCIATED VIRAL VECTORS | 2019 |
|
RU2793735C2 |
MODULATION OF REP PROTEIN ACTIVITY WHEN PRODUCING CLOSED-END DNA (ceDNA) | 2020 |
|
RU2812850C2 |
ISOLATED MODIFIED VPI CAPSID PROTEIN OF ADENO-ASSOCIATED VIRUS OF SEROTYPE 9 (AAV9), CAPSID AND VECTOR BASED THEREON | 2021 |
|
RU2825667C2 |
VARIANTS OF ACID ALPHA-GLUCOSIDASE AND THEIR USE | 2017 |
|
RU2780410C2 |
Authors
Dates
2021-10-28—Published
2017-05-18—Filed